Differentiation of human mesenchymal stem cells to cardiac progenitor cells that promote cardiac repair

• US 8,431,397 B2
• Filed: 09/14/2005
• Issued: 04/30/2013
• Est. Priority Date: 09/14/2004
• Status: Active Grant

• Current Assignee: Trustees Of Columbia University In The City Of New York (Columbia University), The Research Foundation for The State University of New York (State University of New York)
• Original Assignee: Trustees Of Columbia University In The City Of New York (Columbia University)
• Inventors: Robinson, Richard B, Rosen, Michael R, Cohen, Ira S., Brink, Peter R., Gaudette, Glenn, Potapova, Irina
• Primary Examiner(s): Popa, Ileana
• Application Number:
  US11/227,533
• Publication Number:
  US 20060198829A1
• Time in Patent Office: 2,785 Days
• Field of Search: None
• US Class Current: 435/377
• CPC Class Codes: C12N 5/0657 Cardiomyocytes; Heart cells

Abstract

A method for treating a subject afflicted with a cardiac disorder, in vivo, comprises (i) inducing differentiation of a progenitor cell, in vitro, to a cardiogenic cell; and (ii) administering a therapeutically effective amount of the cardiogenic cell of step (i) to the subject, thereby treating the cardiac disorder in the subject. This invention further provides related articles of manufacture and methods.

Claims

1. A method for treating a subject afflicted with a cardiac disorder associated with a loss of cardiac myocytes, in vivo, comprising:

(i) inducing differentiation of human mesenchymal stem cells, in vitro, into cardiogenic cells by forming an embryoid body of the mesenchymal stem cells;

(ii) expanding the cardiogenic cells of step (i) in culture in culture medium comprising serum without additional cardiac myocyte differentiation factors,

(iii) administering a therapeutically effective amount of the cardiogenic cells of step (i) to the subject, thereby treating the cardiac disorder in the subject.

2. The method of claim 1, wherein the subject is a human.

3. The method of claim 1, wherein forming an embryoid body comprises altering the external forces on the mesenchymal stem cells to form the embryoid body or hanging the mesenchymal stem cells to form the embryoid body cell aggregate.

4. The method of claim 1, wherein the administering of step (iii) comprises implanting a patch in the heart of the subject, injection through a catheter, use of microparticles, systemic administration or direct injection through the chest wall.

5. The method of claim 4, wherein the patch is comprised of a urinary bladder membrane scaffold, natural or synthetic scaffold, or pericardium.

6. The method of claim 1, wherein the cardiac disorder is myocardial infarction, cardiomyopathy, congestive heart failure, ventricular septal defect, atrial septal defect, congenital heart defect, ventricular aneurysm, a cardiac disorder which is pediatric in origin, ventricular aneurysm, or a cardiac disorder which requires ventricular reconstruction.

7. A method for inducing differentiation of human mesenchymal stem cells, in vitro, to cardiogenic cells comprising forming an embryoid body of the mesenchymal stem cells thereby inducing the mesenchymal stem cells to differentiate into cardiogenic cells.

8. The method of claim 7, wherein the step of forming an embryoid body comprises altering the external forces on the mesenchymal stem cells to form the embryoid body, or hanging the mesenchymal stem cells to form an embryoid body.

9. Cardiogenic cells made by forming an embryoid body in vitro of mesenchymal stem cells thereby inducing the mesenchymal stem cells to differentiate into cardiogenic cells.

10. The cells of claim 9, wherein the cardiogenic cells and mesenchymal stem cells are human cells.